Next Article in Journal
Utilization of ZeoliticWaste in Alkali-Activated Biomass Bottom Ash Blends
Next Article in Special Issue
Antitumor Activity and Mechanism of Robustic Acid from Dalbergia benthami Prain via Computational Target Fishing
Previous Article in Journal
Complete Microbial Fuel Cell Fabrication Using Additive Layer Manufacturing
Previous Article in Special Issue
Effects of Pyrrole-Imidazole Polyamides Targeting Human TGF-β1 on the Malignant Phenotypes of Liver Cancer Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 13
10.3390/molecules25133052
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Biological Evaluation of Analogs of Didehydroepiandrosterone as Potential New Anticancer Agents

by
Eirik J. Solum
1,*,
Sandra Liekens
2 and
Trond Vidar Hansen
3
1
Faculty of Health Sciences, Nord University, 7801 Namsos, Norway
2
Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Herestraat 49, Postbus 1043, B-3000 Leuven, Belgium
3
School of Pharmacy, Department of Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N-0316 Oslo, Norway
*
Author to whom correspondence should be addressed.
Molecules 2020, 25(13), 3052; https://doi.org/10.3390/molecules25133052
Submission received: 15 June 2020 / Revised: 30 June 2020 / Accepted: 2 July 2020 / Published: 3 July 2020
(This article belongs to the Special Issue Anticancer Compounds with Different Biological Targets)
Browse Figures
Versions Notes

Abstract

:
The synthesis, cytotoxicity and inhibition of CDK8 by thirteen analogs of cortistatin A are reported. These efforts revealed that the analogs with either a 6- or 7-isoquinoline or 5-indole side chain in the 17-position are the most promising anti-proliferative agents. These compounds showed potent cytotoxic effects in CEM, HeLa and HMEC-1 cells. All three compounds exhibited IC50 values < 10µM. The most interesting 10l analog exhibited an IC50 value of 0.59 µM towards the human dermal microvascular endothelial cell line (HMEC-1), significantly lower than the reference standard 2-methoxyestradiol. At a concentration at 50 nM the most potent 10h compound reduced the activity of CDK8 to 35%.

Graphical Abstract

1. Introduction

Steroids are a class of biologically active molecules, important for an array of different physiological effects. Their affinities for various types of nuclear receptors, as well as their safe pharmacological profile have facilitated their widespread application in drug discovery and development [1]. Over recent years, an extensive focus on chemical modification of the steroidal structure has been seen. Such modifications of the steroidal nucleus have yielded several important anticancer molecules and lead compounds. Exemestane (1), [2] abiraterone (2) [3,4] and 2-methoxyestradiol (2-ME) (3) [5,6] are some of the successful examples that have emerged from steroidal pharmacophores, see Figure 1.
A class of compound, the cortistatins, exemplified by cortistatins A (4), see Figure 1, are examples of natural occurring steroid-like structures that have attracted great interest within anti-cancer research [7,8]. In 2006, cortistatin A (4) was the first compound of this group of steroidal-like alkaloids to be isolated from the marine sponge Corticium simplex [9]. The compound was later synthesized, and thoroughly evaluated for its biological effects [10,11,12,13]. Cortistatin A (4) exhibits potent anti-angiogenetic effects, proved by the inhibition of the proliferation of human umbilical vein endothelial cells (HUVECs) in the low nano-molar range [14]. Moreover, cortistatin A (4) is reported to have anti-leukemic activity in vitro and in vivo, and disproportionately induces upregulation of SE-associated genes in CA-sensitive AML cell lines [12]. In addition, several analogs of 5 with interesting anti-cancer effects have been prepared [6,7,8,15,16,17]. Structure-activity-relationship (SAR)-studies have revealed the presence of an isoquinoline group to be crucial for the activity and that the two hydroxyl-groups on the A ring are removable. Along these lines, one of the most interesting analogs reported so far is the amino steroid 5 reported by Corey and co-workers [7].
Herein we present our aim to investigate the biological effects of introducing a variety of nitrogen containing heterocycle systems, inspired by the above mentioned compounds, at the 17-position of didehydroepiandrosterone (DHEA) (6).

2. Results

2.1. Chemistry

The analogs 10a–10m were prepared as depicted in Scheme 1. First, DHEA (6) was converted to the TBS-protected ketone 7. Then the enol-triflate 8 was made from the ketone 7 in a reaction using N-phenyl-bis(trifluoromethanesulfonimide) in the presence of KHMDS at −78 °C. This sequence afforded compound 8 in 85% yield from dehydroepiandrosterone (6). Then compound 8 was employed in a Suzuki Miyaura reaction with different commercially available boronic acids. In the presence of Pd(PPh3)4 and Cs2CO3 in THF/H2O (1:1), the TBS protected compounds 9a–9m were obtained (Scheme 1). Of note, the Suzuki Miyaura reaction with the chlorinated analogs (9c and 9e) proved troublesome, due to the observation of polymerization of the chlorinated boronic acid. The polymeric material was hard to remove during work up, but by slowly adding a solution of the boronic acid in THF to the stirred reaction mixture, we managed to reduce the amount of polymeric material and isolate the desired compounds in decent yield (see Supporting Information). The desired analogs, 10a–10m, were obtained after removal of the TBS-group under standard conditions using TBAF in THF.

2.2. Biological Evaluation

The prepared steroidal analogues 10a–10m were evaluated, together with 2-ME (3), for their antiproliferative effects in two different cancer cell lines, human T-cell leukemia (CEM) and human cervix carcinoma (HeLa) as well as the human dermal microvascular endothelial cell-line HMEC-1. The data are expressed as IC50 (50% inhibitory concentration), which is defined as the compound concentration that reduces cell proliferation by 50%, and are shown in Table 1. The reference compound 2-ME (3) inhibited the growth of all cell lines tested in the low micromolar range (IC50 between 0.4 and 1.6 μM). Among the prepared analogues, the most potent compound proved to be the indole-5-yl analogue of DHEA (10l), with IC50 values of 1.5 ± 0.2 and 2.9 ± 1.0 μM towards the CEM and HeLa cell lines, respectively. Furthermore, the same compound showed potent inhibition of endothelial cell growth with an IC50 value of 0.59 ± 0.07 µM. The corresponding value of 2-ME (3) was 1.3 ± 0.5, which proved that compound 10l was significantly more potent compared towards the HMEC-1 cell line. Unfortunately, among the other compounds the cytotoxic properties were either poor compared to the 2-ME (3) or not present at all.
Inspired by the potent inhibitory activity of cortistatin A (4) towards CDK8, we decided to submit seven of the compounds to a CDK8 inhibition assay. The compounds were tested for their ability to inhibit probe binding to protein kinase CDK8 in vitro at 50 nM concentration. In this assay, the ability of a test compound to compete with an immobilized, active site directed ligand is quantitatively measured and reported as percent of DMSO control (POC), with lower numbers indicating higher binding affinity. The results are displayed in Table 1. Unfortunately, from the results obtained in this assay no correlation between the cytotoxicity of the compounds and their ability to inhibit CDK8 can be seen. The only compound with some probe-binding inhibition properties of CDK8 was compound 10h. The compound has a isoquionline-5-yl side chain attached to the 5-membered D-ring of the steroid core structure.

3. Materials and Methods

3.1. Chemistry

3.1.1. General Methods

All reagents and solvents were used as purchased without further purification unless stated otherwise. Melting points are uncorrected. Analytical TLC was performed using silica gel 60 F254 aluminum plates (Merck). Flash column chromatography was performed on silica gel 60 (40–63 mm) produced by Merck. NMR spectra were recorded on a Bruker Avance DPX-300 MHz or DPX-400 MHz spectrometer for 1H-NMR, and 75 MHz or 101 MHz for 13C-NMR. Coupling constants (J) are reported in Hertz, and chemical shifts are reported in parts per million relative to CDCl3 (7.26 ppm for 1H and 77.0 ppm for 13C). Mass spectra were recorded at 70 eV with Fison’s VG Pro spectrometer. High-resolution mass spectra were performed with a VG Prospecmass spectrometer and with a Micromass Q-TOF-2™. Protocols for the preparation, physical and spectral data of the intermediates 7, 8 and 9a–9m are presented in the supplementary materials.

3.1.2. A General Procedure for the Deprotection

The TBS protected steroids 9a–9m (0.15–0.2 mmol, 1 equiv.) were placed in a dry round-bottomed flask under an argon atmosphere, and dissolved in dry THF (3–4 mL). Tert-butylammoniumfluoride (1 M in THF, 1.1 equiv.) was added dropwise. The reaction mixture was stirred at room temperature (16–18 h). Upon completion, the reaction the mixture was poured into saturated aqueous NaHCO3 (10 mL), and extracted with ethyl acetate (4 × 5 mL). The combined organic extracts were dried (MgSO4) and the solvent evaporated in vacuo. The residues were purified by chromatography (silica gel, 20–50% ethyl acetate in hexane) to give the pure products. The reactions performed were followed by TLC, using cerium ammonium molybdate (CAM) stain to visualize the spots.
(8R,9S,10R,13S,14S)-10,13-Dimethyl-17-phenyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10a). Colorless solid (61 mg, 87%). Purified by column chromatography on silica gel using 20% ethyl acetate in heptane as eluent. Rf = 0.43 (20% ethyl acetate in heptane). 1H NMR (400 MHz, CDCl3) δ 7.37–7.32 (m, 2H), 7.29–7.15 (m, 3H), 6.00–5.68 (m, 1H), 5.50–5.22 (m, 1H), 3.64–3.36 (m, 1H), 2.37–2.14 (m, 3H), 2.12–1.95 (m, 3H), 1.88–1.38 (m, 9H), 1.12–0.99 (m, 8H), 0.89–0.82 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 154.95, 141.27, 137.48, 128.22, 127.32, 126.83, 121.61, 71.90, 57.84, 50.61, 47.37, 42.49, 37.35, 36.87, 35.57, 31.81, 31.76, 31.73, 30.66, 21.10, 19.49, 16.78. HRMS (EI): Exact mass calculated for C25H32NO [M + H]+: 348.2453, found 348.2449.
(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10b). Colourless solid (62 mg, 89%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.21 (50% ethyl acetate in heptane). 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 2.5 Hz, 1H), 8.45 (dd, J = 4.8, 1.7 Hz, 1H), 7.64 (dt, J = 7.9, 1.9 Hz, 1H), 7.25–7.17 (m, 1H), 5.99 (dd, J = 3.3, 1.8 Hz, 1H), 5.52–5.27 (m, 1H), 3.60–3.48 (m, 1H), 2.38–2.20 (m, 3H), 2.15–2.00 (m, 3H), 1.90–1.41 (m, 9H), 1.15–1.01 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 151.81, 147.95, 147.85, 141.34, 133.90, 133.17, 129.42, 123.18, 121.42, 71.79, 57.71, 50.53, 47.50, 42.47, 37.34, 36.85, 35.42, 31.96, 31.79, 31.67, 30.61, 21.03, 19.48, 16.72. HRMS (EI): Exact mass calculated for C24H31NO [M + H]+: 349.2406, found 349.2411.
(3S,8R,9S,10R,13S,14S)-17-(5-Chloropyridin-3-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10c). Colorless solid (56 mg, 73%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.48 (50% ethyl acetate in heptane). 1H NMR (400 MHz, CDCl3) δ 8.49 (d, J = 1.9 Hz, 1H), 8.42 (d, J = 2.3 Hz, 1H), 7.64 (t, J = 2.1 Hz, 1H), 6.05 (dd, J = 3.3, 1.8 Hz, 1H), 5.39 (d, J = 5.2 Hz, 1H), 3.76–3.45 (m, 1H), 2.38–2.21 (m, 3H), 2.13–1.99 (m, 3H), 1.89–1.81 (m, 2H), 1.81–1.42 (m, 8H), 1.15–1.08 (m, 1H), 1.07 (s, 3H), 1.04 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 150.39, 146.43, 145.50, 141.15, 134.21, 133.40, 131.63, 130.95, 121.25, 71.67, 57.53, 50.30, 47.39, 42.28, 37.16, 36.69, 35.17, 31.88, 31.62, 31.47, 30.41, 20.84, 19.34, 16.60. HRMS (EI): Exact mass calculated for C24H30ClNO [M + H]+: 383.2016, found 383.2014.
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-4-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10d). Colorless solid (62 mg, 88%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.17 (50% ethyl acetate in heptane).1H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 5.0 Hz, 2H), 7.26 (dd, J = 4.6, 1.6 Hz, 2H), 6.18 (dd, J = 3.3, 1.8 Hz, 1H), 5.42–5.36 (m, 1H), 3.61–3.47 (m, 1H), 2.38–2.20 (m, 3H), 2.17–2.00 (m, 3H), 1.90–1.40 (m, 9H), 1.17–1.00 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 152.61, 149.57, 144.94, 141.34, 131.83, 121.39, 121.36, 71.82, 57.71, 50.50, 47.31, 42.46, 37.33, 36.85, 35.31, 32.00, 31.79, 31.64, 30.54, 21.01, 19.49, 16.77. HRMS (EI): Exact mass calculated for C24H31NO [M + H]+: 349.2406, found 349.2405.
(3S,8R,9S,10R,13S,14S)-17-(2-Chloropyridin-4-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10e). Colorless solid (50 mg, 65%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.58 (50% ethyl acetate in heptane). 1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 5.2 Hz, 1H), 7.29 (d, J = 1.4 Hz, 1H), 7.18 (dd, J = 5.2, 1.5 Hz, 1H), 6.22 (dd, J = 3.3, 1.9 Hz, 1H), 5.39 (dt, J = 5.2, 2.0 Hz, 1H), 3.54 (tt, J = 11.3, 4.6 Hz, 1H), 2.39–2.20 (m, 3H), 2.14–2.00 (m, 3H), 1.90–1.81 (m, 2H), 1.80–1.39 (m, 8H), 1.17–1.01 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 151.65, 151.47, 149.31, 147.79, 141.16, 133.17, 121.33, 121.20, 119.92, 71.66, 57.51, 50.27, 47.20, 42.27, 37.15, 36.68, 35.04, 31.91, 31.61, 31.44, 30.34, 20.81, 19.33, 16.62. HRMS (EI): Exact mass calculated for C24H30ClNO [M + H]+: 383.2016, found 383.2012.
(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(1H-pyrazol-4-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10f). Colorless solid (28 mg, 41%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.16 (50% ethyl acetate in heptane). 1H NMR (400 MHz, DMSO) δ 12.69 (s, 1H), 7.66 (s, 2H), 5.76 (dd, J = 3.1, 1.7 Hz, 1H), 5.50–5.10 (m, 1H), 4.59 (d, J = 4.5 Hz, 1H), 3.28–3.14 (m, 1H), 2.23–2.05 (m, 4H), 2.05–1.88 (m, 2H), 1.83–1.29 (m, 9H), 1.06–0.94 (m, 5H), 0.90 (s, 3H). 13C NMR (101 MHz, DMSO) δ 145.95, 141.57, 121.66, 120.26, 116.06, 69.98, 56.61, 50.08, 46.33, 42.25, 40.15, 36.83, 36.27, 34.72, 31.41, 31.03, 30.90, 29.96, 20.53, 19.06, 15.92. HRMS (EI): Exact mass calculated for C22H30N2O [M + H]+: 338.2358, found 338.2367.
(3S,8R,9S,10R,13S,14S)-17-(Isoquinolin-4-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10g). Colorless solid (64 mg, 80%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.27 (50% ethyl acetate in heptane). 1H NMR (400 MHz, CDCl3) δ 9.16 (d, J = 0.9 Hz, 1H), 8.33 (s, 1H), 8.03 (dd, J = 8.5, 1.1 Hz, 1H), 7.97 (dt, J = 8.0, 1.1 Hz, 1H), 7.73–7.63 (m, 1H), 7.65–7.55 (m, 1H), 5.87 (dd, J = 3.1, 1.6 Hz, 1H), 5.50–5.34 (m, 1H), 3.68–3.42 (m, 1H), 2.48–2.37 (m, 1H), 2.40–2.18 (m, 3H), 2.19–2.09 (m, 1H), 1.90–1.71 (m, 5H), 1.63–1.43 (m, 5H), 1.17–1.03 (m, 5H), 1.01 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 151.16, 149.65, 141.48, 141.38, 135.81, 132.05, 130.31, 129.54, 128.58, 127.87, 127.18, 125.69, 121.49, 71.87, 57.65, 50.78, 49.75, 42.48, 37.37, 36.94, 35.24, 32.62, 31.86, 31.81, 31.07, 21.01, 19.50, 16.42. HRMS (EI): Exact mass calculated for C28H33NO [M + H]+: 399.2562, found 399.2561.
(3S,8R,9S,10R,13S,14S)-17-(Isoquinolin-5-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10h). Colorless solid (62 mg, 77%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.29 (50% ethyl acetate in heptane). 1H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 8.47 (d, J = 5.9 Hz, 1H), 7.90–7.81 (m, 2H), 7.59–7.53 (m, 1H), 7.48 (dd, J = 7.2, 1.3 Hz, 1H), 5.79 (dd, J = 3.1, 1.6 Hz, 1H), 5.55–5.24 (m, 1H), 3.77–3.36 (m, 1H), 2.45–2.07 (m, 5H), 1.89–1.68 (m, 5H), 1.62–1.43 (m, 5H), 1.16–1.03 (m, 5H), 0.99 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 152.66, 151.24, 142.88, 141.39, 135.54, 135.15, 130.95, 129.61, 129.11, 126.63, 126.44, 121.40, 119.35, 71.72, 57.64, 50.74, 49.62, 42.46, 37.34, 36.90, 35.24, 32.47, 31.82, 31.76, 30.99, 20.96, 19.47, 16.46. HRMS (EI): Exact mass calculated for C28H33NO [M + H]+: 399.2562, found 399.2561.
(3S,8R,9S,10R,13S,14S)-17-(Isoquinolin-6-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10i). Colorless solid (52 mg, 87%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.24 (50% ethyl acetate in heptane). 1H NMR (400 MHz, CDCl3) δ 9.19 (s, 1H), 8.49 (d, J = 5.8 Hz, 1H), 7.88 (dd, J = 8.4, 0.9 Hz, 1H), 7.80–7.74 (m, 1H), 7.66 (dd, J = 8.6, 1.6 Hz, 1H), 7.64–7.57 (m, 1H), 6.16 (dd, J = 3.3, 1.8 Hz, 1H), 5.44–5.37 (m, 1H), 3.62–3.48 (m, 1H), 2.38–2.24 (m, 3H), 2.21 (dt, J = 12.2, 3.6 Hz, 1H), 2.17–2.04 (m, 2H), 1.92–1.45 (m, 9H), 1.15 (s, 5H), 1.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 154.26, 152.07, 143.22, 141.32, 139.49, 136.13, 130.53, 127.72, 127.42, 127.30, 123.05, 121.50, 120.77, 71.86, 57.88, 50.55, 47.61, 42.48, 37.35, 36.87, 35.62, 32.05, 31.81, 31.70, 30.65, 21.12, 19.51, 16.89. HRMS (EI): Exact mass calculated for C28H33NO [M + H]+: 399.2562, found 399.2563.
(3S,8R,9S,10R,13S,14S)-17-(Isoquinolin-7-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10j). Colorless solid (50 mg, 83%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.26 (50% ethyl acetate in heptane). 1H NMR (400 MHz, DMSO) δ 9.32 (s, 1H), 8.44 (d, J = 5.6 Hz, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.93–7.82 (m, 2H), 7.81–7.72 (m, 1H), 6.33–6.15 (m, 1H), 5.41–5.21 (m, 1H), 4.60 (d, J = 4.5 Hz, 1H), 3.29–3.22 (m, 1H), 2.36–1.99 (m, 6H), 1.85–1.50 (m, 7H), 1.49–1.32 (m, 2H), 1.14 (s, 3H), 1.06–0.95 (m, 5H). 13C NMR (101 MHz, DMSO) δ 153.18, 152.54, 142.61, 141.61, 135.26, 134.05, 129.80, 129.13, 128.36, 126.36, 123.32, 120.23, 119.90, 69.98, 57.21, 49.84, 46.67, 42.24, 36.83, 36.26, 34.66, 31.40, 31.27, 30.96, 29.97, 20.52, 19.06, 16.27. HRMS (EI): Exact mass calculated for C28H33NO [M + H]+: 399.2562, found 399.2561.
(3S,8R,9S,10R,13S,14S)-17-(1H-indol-4-yl)-10,13-Dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10k). Colorless solid (60 mg, 78%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.21 (50% ethyl acetate in heptane). 1H NMR (400 MHz, DMSO) δ 11.05 (s, 1H), 7.32–7.21 (m, 2H), 7.02 (t, J = 7.7 Hz, 1H), 6.90 (dd, J = 7.4, 1.0 Hz, 1H), 6.49–6.43 (m, 1H), 5.96 (dd, J = 3.1, 1.7 Hz, 1H), 5.33 (d, J = 5.1 Hz, 1H), 4.59 (d, J = 4.5 Hz, 1H), 3.30–3.22 (m, 1H), 2.34–2.26 (m, 1H), 2.23–2.00 (m, 4H), 1.95–1.88 (m, 1H), 1.80–1.29 (m, 9H), 1.02 (d, J = 9.7 Hz, 8H). 13C NMR (101 MHz, DMSO) δ 153.28, 141.59, 136.06, 128.78, 127.49, 126.77, 124.76, 120.40, 120.30, 116.87, 110.07, 101.27, 69.98, 57.00, 50.07, 47.71, 42.26, 36.86, 36.30, 35.08, 31.54, 31.42, 31.10, 30.18, 20.51, 19.09, 16.69. HRMS (EI): Exact mass calculated for C27H33NO [M + H]+: 387.2562, found 387.2562.
(3S,8R,9S,10R,13S,14S)-17-(1H-Indol-5-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10l). Colorless solid (56 mg, 72%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.18 (50% ethyl acetate in heptane). 1H NMR (400 MHz, DMSO) δ 11.00 (s, 1H), 7.52 (d, J = 1.9 Hz, 1H), 7.37–7.25 (m, 2H), 7.13 (dd, J = 8.4, 1.7 Hz, 1H), 6.45–6.34 (m, 1H), 5.81 (dd, J = 3.0, 1.6 Hz, 1H), 5.32 (d, J = 4.8 Hz, 1H), 4.65–4.53 (m, 1H), 3.29–3.22 (m, 1H), 2.23–2.10 (m, 4H), 2.06–1.94 (m, 2H), 1.82–1.30 (m, 9H), 1.08–0.95 (m, 8H). 13C NMR (101 MHz, DMSO) δ 155.31, 141.58, 134.96, 127.51, 125.38, 123.98, 120.37, 120.27, 117.46, 111.05, 101.28, 69.98, 57.30, 49.95, 46.64, 42.25, 36.84, 36.26, 35.17, 31.40, 31.03, 31.00, 30.07, 20.53, 19.06, 16.50. HRMS (EI): Exact mass calculated for C27H33NO [M + H]+: 387.2562, found 387.2563.
(3S,8R,9S,10R,13S,14S)-17-(1H-Indol-6-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (10m). Colorless solid (53 mg, 69%). Purified by column chromatography on silica gel using 50% ethyl acetate in heptane as eluent. Rf = 0.25 (50% ethyl acetate in heptane). 1H NMR (400 MHz, DMSO) δ 10.91 (s, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.35 (s, 1H), 7.26 (t, J = 2.7 Hz, 1H), 7.02 (dd, J = 8.3, 1.5 Hz, 1H), 6.45–6.17 (m, 1H), 5.92–5.73 (m, 1H), 5.42–5.12 (m, 1H), 4.54 (s, 1H), 3.26–3.18 (m, 1H), 2.21–2.06 (m, 4H), 2.03–1.93 (m, 2H), 1.79–1.26 (m, 9H), 1.06–0.91 (m, 8H). 13C NMR (101 MHz, DMSO) δ 155.05, 141.59, 135.93, 129.50, 126.49, 125.45, 124.72, 120.27, 119.59, 118.25, 108.80, 100.85, 69.98, 57.27, 49.93, 46.67, 42.25, 36.84, 36.27, 35.21, 31.41, 31.03, 30.06, 20.53, 19.07, 16.54. HRMS (EI): Exact mass calculated for C27H33NO [M + H]+: 387.2562, found 387.2563.

3.2. Biological Evaluation

3.2.1. Cell Studies

Human cervical carcinoma (HeLa) cells were seeded in 96-well plates at 15,000 cells/well in the presence of 5-fold dilutions of the compounds. After 3 days of incubation, the cells were trypsinized and counted by means of a Coulter counter (Analis, Leuven, Belgium). Human dermal microvascular endothelial (HMEC-1) cells were seeded on gelatin- coated 48-well plates at 20,000 cells/well. After overnight incubation, 5-fold dilutions of the compounds were added. Three days later, the cells were trypsinized and counted. Human T-cell leukemia (CEM) cells were seeded in 96-well plates at 60,000 cells/well in the presence of the compounds, allowed to proliferate for 4 days and then counted. The 50% inhibitory concentration (IC50) was defined as the compound concentration required to reduce cell proliferation by 50% [18].

3.2.2. Protein Kinase Assay

For the CDK8 profiling we used a kinase selectivity and profiling assay (DiscoveRx) [19]. The assay uses kinase-tagged T7 phage strains which were grown in parallel in 24-well blocks in an Escherichia coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage from a frozen stock (multiplicity of infection = 0.4) and incubated with shaking at 32 °C until lysis (90–150 min). The lysates were centrifuged (6000× g) and filtered (0.2 μm) to remove cell debris. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 min at room temperature to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific phage binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 40× stocks in 100% DMSO and directly diluted into the assay. All reactions were performed in polypropylene 384-well plates in a final volume of 20 µL. The assay plates were incubated at room temperature with shaking for 1 h and the affinity beads were washed with wash buffer (1× PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (1× PBS, 0.05% Tween 20, 0.5 μM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by qPCR. The test compounds were screened at 50 nM, and results for primary screen binding interactions are reported as POC (percent of control). The negative control consists of adding an equal DMSO volume without a test compound and the positive control consist of a control compound. From this POC is calculated: ((test compound signal–positive control signal)/(negative control signal–positive control signal)) × 100%. Negative control = DMSO (100% Ctrl); Positive control = control compound (0% Ctrl), where lower numbers indicate stronger hits in the matrix.

4. Conclusions

Structure-activity relationship (SAR) studies have revealed that steroidal analogs of cortistatin A to act as novel leads for further anti-cancer drug development mediated by inhibition of CDK8 [7,8,20]. In total, 13 new analogs of cortistatin A 4 have been prepared using the Suzuki–Miyaura reaction. All analogs were evaluated for their cytotoxic effects. Additionally, some of the analogs were evaluated for their ability to inhibit CDK8 at 50 nM concentration. The most cytotoxic compounds proved to be compounds 10i, j and l, with either a 6- or 7-isoquinoline attached in the 17 position of the steroidal nucleus This is in accordance with previous literature based on 3-amminosteroids [7,17]. However, the compounds proved less potent than the included standard 2-ME 2. One exception was compound 10l, which exhibited an IC50-value of 0.59 µM towards the HMEC-1 cell line. The compound has a 5-indol ring attached to the 17-position of the steroidal core. No correlation between the ability to inhibit CDK8 and the cytotoxicity was observed, as the most prominent CDK8 inhibitor proved to be compound 10h, with a 5-isoquinoline sidechain attached. Hence, the mechanism behind the toxicity of these compounds cannot be related to inhibition of these enzymes.

Supplementary Materials

The following are available online, Protocols for the preparation, physical and spectral data of the intermediates 7, 8 and 9a–9m.

Author Contributions

Conceptualization, E.J.S. and T.V.H.; methodology, E.J.S., S.L. and T.V.H.; software, E.J.S.; validation, E.J.S., S.L. and T.V.H.; formal analysis, E.J.S.; investigation, E.J.S., S.L. and T.V.H.; resources, E.J.S., S.L. and T.V.H.; data curation, E.J.S., S.L. and T.V.H.; writing—original draft preparation, E.J.S.; writing—review and editing, E.J.S. and T.V.H.; visualization, E.J.S.; supervision, E.J.S.; project administration, E.J.S.; funding acquisition, E.J.S., S.L. and T.V.H.; All authors have read and agreed to the published version of the manuscript.

Funding

The School of Pharmacy, University of Oslo, and Faculty of HealthSciences, Nord University, are gratefully acknowledged for financial support. The authors also express their sincere gratitude towards the European network “Challenging organic syntheses inspired by nature–from natural pro-ducts chemistry to drug discovery” (COST Action CM 1407) for collaborations and fruitful scientific interactions.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Lossignol, D. A little help from steroids in oncology. J. Transl. Int. Med. 2016, 4, 52–54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Coombes, R.C.; Kilburn, L.S.; Snowdon, C.F.; Paridaens, R.; Coleman, R.E.; Jones, S.E.; Jassem, J.; Van de Velde, C.J.H.; Delozier, T.; Alvarez, I.; et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007, 369, 559–570. [Google Scholar] [CrossRef]
  3. Potter, G.A.; Barrie, S.E.; Jarman, M.; Rowlands, M.G. Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer. J. Med. Chem. 1995, 38, 2463–2471. [Google Scholar] [CrossRef] [PubMed]
  4. De Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B., Jr.; Saad, F.; et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011, 364, 1995–2005. [Google Scholar] [CrossRef] [PubMed]
  5. Pribluda, V.S.; Gubish, E.R.; Gubish, E.R.; LaVallee, T.M.; Treston, A.; Swartz, G.M.; Green, S.J. 2-Methoxyestradiol: An Endogenous Antiangiogenic and Antiproliferative Drug Candidate. Cancer Metastasis Rev. 2000, 19, 173–179. [Google Scholar] [CrossRef] [PubMed]
  6. Solum, E.J.; Cheng, J.-J.; Sylte, I.; Vik, A.; Hansen, T.V. Synthesis, biological evaluation and molecular modeling of new analogs of the anti-cancer agent 2-methoxyestradiol: Potent inhibitors of angiogenesis. RSC Adv. 2015, 5, 32497–32504. [Google Scholar] [CrossRef] [Green Version]
  7. Czakó, B.; Kürti, L.; Mammoto, A.; Ingber, D.E.; Corey, E.J. Discovery of Potent and Practical Antiangiogenic Agents Inspired by Cortistatin A. J. Am. Chem. Soc. 2009, 131, 9014–9019. [Google Scholar] [CrossRef] [PubMed]
  8. Hatcher, J.M.; Wang, E.S.; Johannessen, L.; Kwiatkowski, N.; Sim, T.; Gray, N.S. Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. ACS Med. Chem. Lett. 2018, 9, 540–545. [Google Scholar] [CrossRef] [PubMed]
  9. Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M. Cortistatins A, B, C, and D, Anti-angiogenic Steroidal Alkaloids, from the Marine Sponge Corticium simplex. J. Am. Chem. Soc. 2006, 128, 3148–3149. [Google Scholar] [CrossRef] [PubMed]
  10. Nicolaou, K.C.; Sun, Y.-P.; Peng, X.-S.; Polet, D.; Chen, D.Y.K. Total Synthesis of (+)-Cortistatin A. Angew. Chem. Int. 2008, 120, 7420–7423. [Google Scholar] [CrossRef]
  11. Poss, Z.C.; Ebmeier, C.C.; Odell, A.T.; Tangpeerachaikul, A.; Lee, T.; Pelish, H.E.; Shair, M.D.; Dowell, R.D.; Old, W.M.; Taatjes, D.J. Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics. Cell Rep. 2016, 15, 436–450. [Google Scholar] [CrossRef] [Green Version]
  12. Pelish, H.E.; Liau, B.B.; Nitulescu, I.I.; Tangpeerachaikul, A.; Poss, Z.C.; Da Silva, D.H.; Caruso, B.T.; Arefolov, A.; Fadeyi, O.; Christie, A.L.; et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 2015, 526, 273–276. [Google Scholar] [CrossRef] [PubMed]
  13. Flyer, A.N.; Si, C.; Myers, A.G. Synthesis of cortistatins A, J, K and L. Nat. Chem. 2010, 2, 886. [Google Scholar] [CrossRef] [PubMed]
  14. Watanabe, Y.; Aoki, S.; Tanabe, D.; Setiawan, A.; Kobayashi, M. Cortistatins E, F, G, and H, four novel steroidal alkaloids from marine sponge Corticium simplex. Tetrahedron 2007, 63, 4074–4079. [Google Scholar] [CrossRef]
  15. Solum, E.J.; Cheng, J.-J.; Sørvik, I.B.; Paulsen, R.E.; Vik, A.; Hansen, T.V. Synthesis and biological evaluations of new analogs of 2-methoxyestradiol: Inhibitors of tubulin and angiogenesis. Eur. J. Med. Chem. 2014, 85, 391–398. [Google Scholar] [CrossRef] [PubMed]
  16. al-Kazaale, N.; Tran, P.T.; Haidari, F.; Solum, E.J.; Liekens, S.; Vervaeke, P.; Sylte, I.; Cheng, J.-J.; Vik, A.; Hansen, T.V. Synthesis, molecular modeling and biological evaluation of potent analogs of 2-methoxyestradiol. Steroids 2018, 136, 47–55. [Google Scholar] [CrossRef] [PubMed]
  17. Solum, E.; Hansen, T.V.; Aesoy, R.; Herfindal, L. New CDK8 inhibitors as potential anti-leukemic agents—Design, synthesis and biological evaluation. Bioorganic Med. Chem. 2020, 28, 115461. [Google Scholar] [CrossRef] [PubMed]
  18. Canela, M.-D.; Pérez-Pérez, M.-J.; Noppen, S.; Sáez-Calvo, G.; Díaz, J.F.; Camarasa, M.-J.; Liekens, S.; Priego, E.-M. Novel Colchicine-Site Binders with a Cyclohexanedione Scaffold Identified through a Ligand-Based Virtual Screening Approach. J. Med. Chem. 2014, 57, 3924–3938. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Fabian, M.A.; Biggs Iii, W.H.; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; Benedetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; et al. A small molecule–kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329. [Google Scholar] [CrossRef] [PubMed]
  20. Gansbeke, K.V.; Solum, E.J.; Liekens, S.; Vik, A.; Hansen, T.V. Regioselective monoalkylation of 17β-estradiol for the synthesis of cytotoxic estrogens. Steroids 2017, 124, 54–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Sample Availability: Samples of the compounds 10a–10m are available from the authors.
Molecules 25 03052 g001 550
Figure 1. Chemical structures of biological active steroidal compounds.
Figure 1. Chemical structures of biological active steroidal compounds.
Molecules 25 03052 g001
Molecules 25 03052 sch001 550
Scheme 1. Synthesis of compounds 10a–10m. Reagents and conditions: (i) TBSCl, imidazole, DMF rt., 5h, 96% (ii) KHMDS, PhN(SO2CF3)2, THF, −78 °C, 4 h, 89%; (iii) ArB(OH)2, Cs2CO3, Pd(Ph3P)4, THF:H2O (1:1) 60 °C, 5 h, 53–88%; (iv) TBAF, THF, rt., 41–89%.
Scheme 1. Synthesis of compounds 10a–10m. Reagents and conditions: (i) TBSCl, imidazole, DMF rt., 5h, 96% (ii) KHMDS, PhN(SO2CF3)2, THF, −78 °C, 4 h, 89%; (iii) ArB(OH)2, Cs2CO3, Pd(Ph3P)4, THF:H2O (1:1) 60 °C, 5 h, 53–88%; (iv) TBAF, THF, rt., 41–89%.
Molecules 25 03052 sch001
Table
Table 1. Biological evaluation of compounds 10a–10m.
Table 1. Biological evaluation of compounds 10a–10m.
CompoundCEM
Cell Assay
IC50 (µM) a		HeLa
Cell Assay
IC50 (µM) a		HMEC-1
Cell Assay
IC50 (µM) a		CDK8
Per Cent of Control (POC)
10a>100>100>100n.d. b
10b16 ± 390 ± 1417 ± 4n.d.
10c18 ± 497 ± 460 ± 495%
10d>1002.1 ± 1.788 ± 8n.d.
10e10 ± 118 ± 118.2 ± 1.9100%
10f24 ± 167.0 ± 2.511 ± 1n.d.
10g14 ± 124 ± 615 ± 0n.d.
10h16 ± 224 ± 813 ± 032%
10i5.4 ± 0.69.2 ± 0.92.6 ± 0.4100%
10j5.8 ± 3.18.7 ± 0.05.4 ± 3.6100%
10k26 ± 1791 ± 128.4 ± 4.3100%
10l1.5 ± 0.22.9 ± 1.00.59 ± 0.07100%
10m50 ± 2144 ± 214 ± 2n.d.
2-ME (3)1.6 ± 0.9 0.41 ± 0.061.3 ± 0.5n.d.
a Results of three experiments performed as triplicates, b n.d = not determined.

Share and Cite

MDPI and ACS Style

J. Solum, E.; Liekens, S.; Hansen, T.V. Synthesis and Biological Evaluation of Analogs of Didehydroepiandrosterone as Potential New Anticancer Agents. Molecules 2020, 25, 3052. https://doi.org/10.3390/molecules25133052

AMA Style

J. Solum E, Liekens S, Hansen TV. Synthesis and Biological Evaluation of Analogs of Didehydroepiandrosterone as Potential New Anticancer Agents. Molecules. 2020; 25(13):3052. https://doi.org/10.3390/molecules25133052

Chicago/Turabian Style

J. Solum, Eirik, Sandra Liekens, and Trond Vidar Hansen. 2020. "Synthesis and Biological Evaluation of Analogs of Didehydroepiandrosterone as Potential New Anticancer Agents" Molecules 25, no. 13: 3052. https://doi.org/10.3390/molecules25133052

Article Metrics

Back to TopTop